Scholar Rock posted a Q2 net loss of USD 109.9 million, versus a net loss of USD 110 million a year earlier; loss per share narrowed to USD 0.84 from USD 0.98.
No revenue was recorded; R&D expense fell 6.7% to USD 58.2 million, while G&A expense rose 1.9% to USD 50.7 million.
Cash, cash equivalents, and marketable securities climbed to USD 492.1 million at June 30, 2026, including USD 62.8 million of net ATM proceeds.
Apitegromab FDA review advances toward September decision
FDA review of the apitegromab BLA advanced with two fill-finish facilities, supporting an approval decision by the Sept. 30, 2026 PDUFA date.
CEO David L. Hallal said the company is prepared for a U.S. apitegromab launch immediately upon FDA approval, which could come any time through Sept. 30, 2026.
SRRK•
